F9 and hemophilia: Therefore, our group previously tested the ability of liver-directed AAV-fVIII gene therapy to eradicate fVIII inhibitors in hemophilia A mice and found that, unlike liver-directed fIX expression in hemophilia B mice, liver-directed fVIII gene therapy in the pre-immunized hemophilia A setting did not eradicate inhibitors (22).